Related News

• This GLP-1 Stock Could Double by 2030. Here's Why | 2026-07-16
  Investors need to ask tough questions before initiating a position in this biotech company.
• Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy | 2026-07-16
  Eli Lilly announced it is buying AtaiBeckley in a bet on neuroscience and psychiatric pharmaceuticals.
• Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | 2026-07-16
  AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli...
• If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today | 2026-07-15
  Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.
• 3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech | 2026-07-15
  With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.
• 2 Beaten-Down GLP-1 Stocks to Buy on the Dip | 2026-07-15
  Don't wait until clinical milestones send their share prices soaring.
• Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In Broader Cancers | 2026-07-15
  FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...
• What Could Power The Next Rally In META Stock | 2026-07-14
  While the company's AI spending commands attention, the real story is how the technology is already accelerating the core business that funds it all.
• Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? | 2026-07-14
  Eyes are on the rollout of Lilly's new weight loss pill.
• Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades | 2026-07-13
  Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.

News source: finlight